AWA
PDLI

Arete Wealth Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Arete Wealth Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,681
Closed -$37K – 357
2017
Q4 		$37K Sell
13,681
-65
-0.5% -$200 0.01% 310
2017
Q3 		$47K Buy
+13,746
New +$38.2K 0.02% 265

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Arete Wealth Advisors's PDLI Position: Q1 2018 in Review

Arete Wealth Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 13,681 shares — an estimated $37K sold.

Arete Wealth Advisors first reported a position in PDLI in Q3 2017 and held it in 2 quarters. The position peaked at $47K in Q3 2017. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

  • Arete Wealth Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
  • Arete Wealth Advisors sold 13,681 PDL BioPharma, Inc. shares in Q1 2018, an estimated $37K.
  • Arete Wealth Advisors first reported a position in PDL BioPharma, Inc. in Q3 2017 and held it in 2 quarters.
  • Arete Wealth Advisors's PDL BioPharma, Inc. position peaked at $47K in Q3 2017.
  • 176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on Arete Wealth Advisors's 13F filing for Q1 2018, filed 15 May 2018.